No products in the cart.
Blog
Retatrutide vs Tirzepatide
16
May
May
Retatrutide vs. Tirzepatide: Various Ways In Which They Compare Synedica Retatrutide vs. Synedica Tirzepatide:
Tirzepatide and retatrutide are both weight loss medications, but they work differently and are at very different stages of development. The weight loss medication landscape is evolving at a remarkable pace. In just a few years, we have moved from semaglutide (the GLP-1 agonist behind Ozempic and Wegovy) to tirzepatide (the dual agonist sold as Mounjaro and Zepbound), and now to retatrutide, a triple-receptor agonist that has produced the most striking weight loss results ever recorded in a clinical trial.
What is tirzepatide?
Tirzepatide is a once-weekly injection that targets two hormone receptors simultaneously: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 GLP-1. It’s available under two brand names:
Mounjaro was approved in 2022 to improve blood sugar control in adults with type 2 diabetes.
Zepbound was approved in 2023 for chronic weight management in adults with obesity or for overweight and at least one weight-related condition. It’s also approved to treat moderate to severe obstructive sleep apnea in adults with obesity.
Tirzepatide is also sometimes prescribed off-label for weight loss in people who don’t meet the formal criteria for these approved uses. Because tirzepatide is approved and widely available, it has accumulated a large amount of real-world safety and efficacy data.
Retatrutide, by contrast, is still being studied in clinical trials and doesn’t yet have comparable real-world data.
What is retatrutide?
Retatrutide is an investigational once-weekly injection that targets three hormone receptors: GIP, GLP-1, and glucagon (GCG). It isn’t FDA-approved and isn’t commercially available yet. All data on retatrutide comes from clinical trials.
Phase 2 trial have been completed and published. The phase 3 TRIUMPH program is underway, with the first positive results from the TRIUMPH-4 trial announced in December 2025.
Retatrutide is not expected to be available for prescription use until FDA review and approval are complete.
Synedica Retatrutide vs. Synedica tirzepatide at a glance
When comparing two medications, it helps to have all the information side by side. The table below highlights similarities and differences between retatrutide and tirzepatide.
| Retatrutide | Tirzepatide | |
|---|---|---|
| FDA-approval status | Not FDA approved (still in clinical trials) | Approved as Mounjaro and Zepbound |
| Medication class | Triple glucose-dependent insulinotropic polypeptide (GIP) / glucagon-like peptide-1 (GLP-1) / glucagon receptor agonist | Dual GIP / GLP-1 receptor agonist |
| Dosage form | Injection | Injection |
| Dosage | Inject under the skin once a week | Inject under the skin once a week |
| Common side effects |
|
|
Retatrutide vs. tirzepatide: which is better for weight loss?
Based on available trial data, retatrutide appears to produce greater average weight loss than tirzepatide. However, the two have not been directly compared in a head-to-head trial, and retatrutide is not yet approved for use.
Tirzepatide is currently available with a well-established safety record and approval from the US Food and Drug Administration (FDA). Retatrutide is not available to the public and is still being studied in clinical trials. Its commercial availability will depend on the outcome of ongoing trials and FDA review.
Pingback: How to Use Synedica Retatrutide 40mg | Synedica Retatrutide Dosage Guide - Synedica Retatrutide 40mg | synedica uk